Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CTKB
stocks logo

CTKB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
57.09M
-0.67%
0.015
-87.01%
44.10M
+6.38%
-0.040
+47.06%
49.74M
+9.06%
-0.015
+110.67%
Estimates Revision
The market is revising Upward the revenue expectations for Cytek Biosciences, Inc. (CTKB) for FY2025, with the revenue forecasts being adjusted by 0.27% over the past three months. During the same period, the stock price has changed by 29.35%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.27%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-250%
In Past 3 Month
Stock Price
Go Up
up Image
+29.35%
In Past 3 Month
Wall Street analysts forecast CTKB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTKB is 5.75 USD with a low forecast of 4.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CTKB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTKB is 5.75 USD with a low forecast of 4.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.200
sliders
Low
4.00
Averages
5.75
High
7.50
Current: 5.200
sliders
Low
4.00
Averages
5.75
High
7.50
Piper Sandler
Overweight
downgrade
$8
2025-11-11
Reason
Piper Sandler
Price Target
$8
2025-11-11
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Cytek Biosciences to $7.50 from $8 keeps an Overweight rating on the shares. The firm cites the company's quarterly results for the price target change.
Morgan Stanley
Equal Weight
downgrade
$7 -> $4
2025-08-10
Reason
Morgan Stanley
Price Target
$7 -> $4
2025-08-10
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Cytek Biosciences to $4 from $7 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says recurring revenue strength offset weakness in the company's instrument segment. It believes Cytek's visibility remains limited.
Morgan Stanley
Equal Weight
downgrade
$9 -> $7
2025-05-28
Reason
Morgan Stanley
Price Target
$9 -> $7
2025-05-28
downgrade
Equal Weight
Reason
Stephens
Overweight
maintain
$6 -> $4
2025-05-16
Reason
Stephens
Price Target
$6 -> $4
2025-05-16
maintain
Overweight
Reason
TD Cowen
Buy
to
Hold
downgrade
$7 -> $4
2025-05-09
Reason
TD Cowen
Price Target
$7 -> $4
2025-05-09
downgrade
Buy
to
Hold
Reason
TD Cowen downgraded Cytek Biosciences to Hold from Buy with a price target of $4, down from $7. The company's Q1 missed as multiple headwinds persist and the fiscal 2025 guidance was lowered, the analyst tells investors in a research note. The firm says that while Cytek remains a dominant flow cytometry player, it would stay on the sidelines pending better clarity on a path back to sustained growth.
Stephens & Co.
Mason Carrico
Buy
Reiterates
$6
2025-03-19
Reason
Stephens & Co.
Mason Carrico
Price Target
$6
2025-03-19
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cytek Biosciences Inc (CTKB.O) is -173.33, compared to its 5-year average forward P/E of 83.90. For a more detailed relative valuation and DCF analysis to assess Cytek Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
83.90
Current PE
-173.33
Overvalued PE
173.10
Undervalued PE
-5.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
50.17
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
89.78
Undervalued EV/EBITDA
10.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.81
Current PS
0.00
Overvalued PS
11.99
Undervalued PS
1.64
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

CTKB News & Events

Events Timeline

(ET)
2025-12-01
16:30:00
Morgan Stanley Initiates Coverage on Cytek Biosciences with Equal Weight Rating and $6 Price Target
select
2025-11-05 (ET)
2025-11-05
16:55:29
Cytek Biosciences Supports FY25 Revenue Forecast of $196M-$205M, Exceeding Consensus of $195.95M
select
2025-11-05
16:54:36
Cytek Biosciences Announces Q3 Earnings Per Share of 4 Cents, Exceeding Consensus of 1 Cent
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-14Benzinga
Major Stocks Including Legence, Cidara Therapeutics, Avadel Pharmaceuticals, and Omeros Rise on Friday

  • U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones index dropping over 500 points on Friday, while Legence Corp's shares rose 10.7% despite mixed earnings results.

  • Legence Corp Earnings Report: Legence Corp reported a revenue increase of 26.2% year-over-year to $708.01 million, but missed earnings expectations with a loss of 2 cents per share.

  • Significant Stock Gains: Cidara Therapeutics saw a 105.6% increase after being acquired by Merck, while other companies like Invivyd Inc and Scholar Rock also experienced notable gains following positive financial results.

  • Other Notable Performers: Several stocks, including Avadel Pharmaceuticals and Beyond Meat, recorded gains due to various factors such as unsolicited proposals and financial announcements.

[object Object]
Preview
3.5
11-13Newsfilter
TIME Names Cytek® Biosciences Among America's Growth Leaders for 2026

  • Cytek Biosciences Recognition: Cytek Biosciences has been named one of TIME's America's Growth Leaders for 2026, highlighting its exceptional growth, financial stability, and stock performance over the past five years.

  • Innovative Technology: The company is recognized for its Full Spectrum Profiling™ (FSP®) technology, which enhances flow cytometry and supports advancements in cancer research, cell and gene therapies, and vaccine development.

  • Commitment to Accessibility: Cytek aims to make high-parameter cell analysis more accessible and cost-effective for laboratories of all sizes, reflecting its dedication to advancing human health and scientific understanding.

  • Global Impact: Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, demonstrating their significant influence on research and the broader scientific community.

[object Object]
Preview
2.0
11-06NASDAQ.COM
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead

  • RxSight's After-Hours Surge: RxSight shares jumped 18.1% after reporting a wider net loss and a 14% revenue decline, but improved its full-year revenue guidance and gross margin outlook.

  • Penumbra's Strong Performance: Penumbra's stock rose 16.4% following a strong Q3 with increased net income and revenue, along with a raised full-year revenue forecast.

  • Evolus Continues Gains: Evolus saw a 13.5% increase in after-hours trading after narrowing its net loss and reporting revenue growth, while reaffirming its full-year revenue guidance.

  • Modest Growth for Other Companies: CVRx and Cytek Biosciences also experienced after-hours gains, with CVRx reporting a slight improvement in losses and revenue growth, while Cytek reaffirmed its future revenue guidance despite a net loss.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cytek Biosciences Inc (CTKB) stock price today?

The current price of CTKB is 5.2 USD — it has decreased -2.99 % in the last trading day.

arrow icon

What is Cytek Biosciences Inc (CTKB)'s business?

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

arrow icon

What is the price predicton of CTKB Stock?

Wall Street analysts forecast CTKB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTKB is 5.75 USD with a low forecast of 4.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cytek Biosciences Inc (CTKB)'s revenue for the last quarter?

Cytek Biosciences Inc revenue for the last quarter amounts to 52.29M USD, increased 1.54 % YoY.

arrow icon

What is Cytek Biosciences Inc (CTKB)'s earnings per share (EPS) for the last quarter?

Cytek Biosciences Inc. EPS for the last quarter amounts to -0.04 USD, decreased -500.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cytek Biosciences Inc (CTKB)'s fundamentals?

The market is revising Upward the revenue expectations for Cytek Biosciences, Inc. (CTKB) for FY2025, with the revenue forecasts being adjusted by 0.27% over the past three months. During the same period, the stock price has changed by 29.35%.
arrow icon

How many employees does Cytek Biosciences Inc (CTKB). have?

Cytek Biosciences Inc (CTKB) has 648 emplpoyees as of December 05 2025.

arrow icon

What is Cytek Biosciences Inc (CTKB) market cap?

Today CTKB has the market capitalization of 664.90M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free